Evidence map›Paper›PMID 25282044›Full record

ArticleNature nanotechnology2014

Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy.

Joo Eun Chung, Susi Tan, Shu Jun Gao, Nunnarpas Yongvongsoontorn, Soon Hee Kim, Jeong Heon Lee, Hak Soo Choi, Hirohisa Yano, Lang Zhuo, Motoichi Kurisawa and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature nanotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 1 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 1 synthesis or guideline pooled it, 410 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Joo Eun Chung *Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Susi Tan *Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Shu Jun GaoInstitute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Nunnarpas YongvongsoontornInstitute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Soon Hee KimDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215 USA.
Jeong Heon LeeDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215 USA.
Hak Soo ChoiDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215 USA.
Hirohisa YanoInstitute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Lang ZhuoInstitute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Motoichi KurisawaInstitute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Jackie Y YingInstitute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore.
Institute of Bioengineering and Nanotechnology · SGBeth Israel Deaconess Medical Center · USKurume University · JP

Funding

Image-Guided Surgery of Endocrine Glands and Their Tumors using Near-Infrared FluR01EB011523 · NIBIB · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHOI, HAK SOO · 2010 to 2013
$2.0M
NIBIB NIH HHS R01 EB011523NIBIB NIH HHS R01-EB-011523
6 · The paper itself

Abstract

When designing drug carriers, the drug-to-carrier ratio is an important consideration, because the use of high quantities of carriers can result in toxicity as a consequence of poor metabolism and elimination of the carriers. However, these issues would be of less concern if both the drug and carrier had therapeutic effects. (-)-Epigallocatechin-3-O-gallate (EGCG), a major ingredient of green tea, has been shown, for example, to possess anticancer effects, anti-HIV effects, neuroprotective effects and DNA-protective effects. Here, we show that sequential self-assembly of the EGCG derivative with anticancer proteins leads to the formation of stable micellar nanocomplexes, which have greater anticancer effects in vitro and in vivo than the free protein. The micellar nanocomplex is obtained by complexation of oligomerized EGCG with the anticancer protein Herceptin to form the core, followed by complexation of poly(ethylene glycol)-EGCG to form the shell. When injected into mice, the Herceptin-loaded micellar nanocomplex demonstrates better tumour selectivity and growth reduction, as well as longer blood half-life, than free Herceptin.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisCatechinCell Line, TumorDrug CarriersHumansMiceMicellesMice, NudeNeoplasmsTrastuzumabAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCatechinDrug Carriersepigallocatechin gallateMicellesTrastuzumab

Identifiers

PMID25282044
PMCPMC4221637
OpenAlexW1976595844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.